Review:
Gene Therapy Approaches For Muscular Dystrophies
overall review score: 4.2
⭐⭐⭐⭐⭐
score is between 0 and 5
Gene therapy approaches for muscular dystrophies aim to treat or manage these inherited neuromuscular disorders by delivering or modifying genetic material within affected muscle cells. These strategies seek to restore, compensate, or correct defective genes responsible for conditions such as Duchenne Muscular Dystrophy, employing vectors like adeno-associated viruses (AAV), exon skipping techniques, and gene editing tools like CRISPR-Cas9.
Key Features
- Use of viral vectors (e.g., AAV) to deliver therapeutic genes
- Exon skipping strategies to bypass genetic mutations
- Gene editing technologies such as CRISPR-Cas9 for precise genetic correction
- Potential to provide long-term or permanent treatment effects
- Targeted delivery to muscle tissue with ongoing research to improve efficiency
- Currently in various stages of clinical trials and preclinical studies
Pros
- Offers the potential for disease modification or cure
- Multiple approaches can be tailored to individual genetic mutations
- Advances in vector technology have improved safety and efficacy
- Potential to significantly improve quality of life for patients
Cons
- Challenges in achieving efficient and widespread delivery to all affected muscles
- Risk of immune responses against viral vectors or introduced proteins
- Limited long-term data on durability and safety
- High development costs and complex manufacturing processes
- Genetic heterogeneity complicates universal application